NEW YORK (GenomeWeb) – Alere today announced that its shareholders have voted to approve the company's acquisition by Abbott. Alere said that more than 98 percent of the votes cast at a special meeting — representing 77 percent of outstanding Alere shares on Aug. 26 — voted in favor of the acquisition.

"The overwhelming support we received from our shareholders today is recognition of the significant value that the combination of Alere and Abbott unlocks for our global customers, employees, and shareholders," Alere President and CEO Namal Nawana said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.